{
    "xml": "<topic id=\"PHP1582\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/streptokinase\" basename=\"streptokinase\" title=\"STREPTOKINASE\">\n<title>STREPTOKINASE</title>\n<body>\n<data name=\"vtmid\">319810009</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_431464079\" title=\"Tissue plasminogen activators\">Tissue plasminogen activators</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34567\" title=\"FIBRINOLYTICS\" namespace=\"/drug-classes/fibrinolytics\">FIBRINOLYTICS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\n</body>\n<topic id=\"PHP70787\" outputclass=\"indicationsAndDose\" rev=\"1.14\" parent=\"/drugs/streptokinase\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Acute myocardial infarction</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1&#8239;500&#8239;000&#8239;units, to be initiated within 12 hours of symptom onset, dose to be given over 60 minutes.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Deep-vein thrombosis</p>\n<p outputclass=\"therapeuticIndication\">Pulmonary embolism</p>\n<p outputclass=\"therapeuticIndication\">Acute arterial thromboembolism</p>\n<p outputclass=\"therapeuticIndication\">Central retinal venous or arterial thrombosis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>250&#8239;000&#8239;units, dose to be given over 30 minutes, then 100&#8239;000&#8239;units every 1&#8239;hour for up to 12&#8211;72 hours, duration is adjusted according to condition with monitoring of clotting parameters (consult product literature).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70847\" outputclass=\"contraindications\" rev=\"1.13\" parent=\"/drugs/streptokinase\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"importantAdvice\">\n<title>Contra-indications, further information</title>\n<sectiondiv>\n<p>Prolonged persistence of antibodies to streptokinase and anistreplase (no longer available) can reduce the effectiveness of subsequent treatment; therefore, streptokinase should not be used again beyond 4 days of first administration of either streptokinase or anistreplase.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70731\" outputclass=\"sideEffects\" rev=\"1.11\" parent=\"/drugs/streptokinase\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Guillain-Barr&#233; syndrome</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70882\" outputclass=\"allergyAndCrossSensitivity\" rev=\"1.18\" parent=\"/drugs/streptokinase\">\n<title>Allergy and cross-sensitivity</title>\n<body>\n<section outputclass=\"allergyAndCrossSensitivityContraindications\">\n<sectiondiv>\n<p>Contraindicated if previous allergic reaction to either streptokinase or anistreplase (no longer available).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70901\" outputclass=\"directionsForAdministration\" rev=\"1.12\" parent=\"/drugs/streptokinase\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>For <i>intravenous infusion</i> (<i>Streptase</i>\n<tm tmtype=\"reg\"/>), give continuously or intermittently; reconstitute with sodium chloride 0.9%, then dilute further with Glucose 5% or Sodium Chloride 0.9% after reconstitution.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP1582-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/streptokinase\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77029\" title=\"Powder for solution for infusion\" namespace=\"/drugs/streptokinase/powder-for-solution-for-infusion\">Powder for solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78101\" namespace=\"/treatment-summaries/fibrinolytic-drugs\" title=\"Fibrinolytic drugs\" count=\"3\" rel=\"backlink\">Fibrinolytic drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34567\" namespace=\"/drug-classes/fibrinolytics\" title=\"FIBRINOLYTICS\" count=\"1\" rel=\"link\">FIBRINOLYTICS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77029\" namespace=\"/drugs/streptokinase/powder-for-solution-for-infusion\" title=\"Powder for solution for infusion\" count=\"1\" rel=\"link\">Powder for solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP1582",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/streptokinase",
    "basename": "streptokinase",
    "title": "STREPTOKINASE",
    "vtmid": "319810009",
    "drugClassification": [
        "Tissue plasminogen activators"
    ],
    "inheritsFromClass": [
        "FIBRINOLYTICS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Acute myocardial infarction",
                        "html": "Acute myocardial infarction"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "1 500 000 units, to be initiated within 12 hours of symptom onset, dose to be given over 60 minutes.",
                        "html": "<p>1&#8239;500&#8239;000&#8239;units, to be initiated within 12 hours of symptom onset, dose to be given over 60 minutes.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Deep-vein thrombosis",
                        "html": "Deep-vein thrombosis"
                    },
                    {
                        "textContent": "Pulmonary embolism",
                        "html": "Pulmonary embolism"
                    },
                    {
                        "textContent": "Acute arterial thromboembolism",
                        "html": "Acute arterial thromboembolism"
                    },
                    {
                        "textContent": "Central retinal venous or arterial thrombosis",
                        "html": "Central retinal venous or arterial thrombosis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "250 000 units, dose to be given over 30 minutes, then 100 000 units every 1 hour for up to 12&#8211;72 hours, duration is adjusted according to condition with monitoring of clotting parameters (consult product literature).",
                        "html": "<p>250&#8239;000&#8239;units, dose to be given over 30 minutes, then 100&#8239;000&#8239;units every 1&#8239;hour for up to 12&#8211;72 hours, duration is adjusted according to condition with monitoring of clotting parameters (consult product literature).</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "textContent": "Prolonged persistence of antibodies to streptokinase and anistreplase (no longer available) can reduce the effectiveness of subsequent treatment; therefore, streptokinase should not be used again beyond 4 days of first administration of either streptokinase or anistreplase.",
                "html": "<p>Prolonged persistence of antibodies to streptokinase and anistreplase (no longer available) can reduce the effectiveness of subsequent treatment; therefore, streptokinase should not be used again beyond 4 days of first administration of either streptokinase or anistreplase.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Guillain-Barr&#233; syndrome",
                        "html": "Guillain-Barr&#233; syndrome",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ]
            }
        }
    },
    "allergyAndCrossSensitivity": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Contraindicated if previous allergic reaction to either streptokinase or anistreplase (no longer available).",
                "html": "<p>Contraindicated if previous allergic reaction to either streptokinase or anistreplase (no longer available).</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous infusion (Streptase ), give continuously or intermittently; reconstitute with sodium chloride 0.9%, then dilute further with Glucose 5% or Sodium Chloride 0.9% after reconstitution.",
                "html": "<p>For <i>intravenous infusion</i> (<i>Streptase</i>\n<tm tmtype=\"reg\"/>), give continuously or intermittently; reconstitute with sodium chloride 0.9%, then dilute further with Glucose 5% or Sodium Chloride 0.9% after reconstitution.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77029",
                "label": "Powder for solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78101",
                "label": "Fibrinolytic drugs",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "drugClass": [
            {
                "id": "PHP34567",
                "label": "FIBRINOLYTICS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77029",
                "label": "Powder for solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}